174 related articles for article (PubMed ID: 37926347)
1. Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges.
Srilatha M; Malla R; Adem MP; Foote JB; Nagaraju GP
Semin Cancer Biol; 2023 Dec; 97():12-20. PubMed ID: 37926347
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies.
Osei-Bordom DC; Serifis N; Brown ZJ; Hewitt DB; Lawal G; Sachdeva G; Cloonan DJ; Pawlik TM
Surg Oncol; 2022 Aug; 43():101803. PubMed ID: 35830772
[TBL] [Abstract][Full Text] [Related]
3. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions.
Bandi DSR; Sarvesh S; Farran B; Nagaraju GP; El-Rayes BF
Cytokine Growth Factor Rev; 2023; 71-72():26-39. PubMed ID: 37407355
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.
Kuznetsova A; Popova O; Panchenkov D; Dyuzheva T; Ivanov A
Clin Exp Med; 2023 Jul; 23(3):619-643. PubMed ID: 36085429
[TBL] [Abstract][Full Text] [Related]
5. Obesity-Induced Adipose Tissue Inflammation as a Strong Promotional Factor for Pancreatic Ductal Adenocarcinoma.
Chang HH; Eibl G
Cells; 2019 Jul; 8(7):. PubMed ID: 31277269
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer.
Polvani S; Tarocchi M; Tempesti S; Bencini L; Galli A
World J Gastroenterol; 2016 Feb; 22(8):2441-59. PubMed ID: 26937133
[TBL] [Abstract][Full Text] [Related]
7. Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.
Incio J; Liu H; Suboj P; Chin SM; Chen IX; Pinter M; Ng MR; Nia HT; Grahovac J; Kao S; Babykutty S; Huang Y; Jung K; Rahbari NN; Han X; Chauhan VP; Martin JD; Kahn J; Huang P; Desphande V; Michaelson J; Michelakos TP; Ferrone CR; Soares R; Boucher Y; Fukumura D; Jain RK
Cancer Discov; 2016 Aug; 6(8):852-69. PubMed ID: 27246539
[TBL] [Abstract][Full Text] [Related]
8. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
9. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
10. The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics.
Qian J; Zhang X; Wei B; Tang Z; Zhang B
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188943. PubMed ID: 37355177
[TBL] [Abstract][Full Text] [Related]
11. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
12. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
Herting CJ; Karpovsky I; Lesinski GB
Cancer Metastasis Rev; 2021 Sep; 40(3):675-689. PubMed ID: 34591240
[TBL] [Abstract][Full Text] [Related]
13. Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity.
Chamma H; Vila IK; Taffoni C; Turtoi A; Laguette N
Cancer Lett; 2022 Jul; 538():215694. PubMed ID: 35489447
[TBL] [Abstract][Full Text] [Related]
14. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
Peters ML; Tseng JF; Miksad RA
Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
[TBL] [Abstract][Full Text] [Related]
15. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy.
Luong T; Golivi Y; Nagaraju GP; El-Rayes BF
Cytokine Growth Factor Rev; 2022 Dec; 68():107-115. PubMed ID: 36096869
[TBL] [Abstract][Full Text] [Related]
17. Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins.
Liot S; Balas J; Aubert A; Prigent L; Mercier-Gouy P; Verrier B; Bertolino P; Hennino A; Valcourt U; Lambert E
Front Immunol; 2021; 12():612271. PubMed ID: 33889150
[TBL] [Abstract][Full Text] [Related]
18. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
19. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
[TBL] [Abstract][Full Text] [Related]
20. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
